Galecto Raises $316.3 Million in Public Offering to Advance Blood Cancer Therapeutics Pipeline
核心洞察
Galecto (搜索) completed a successful public offering of 16.6 million shares at $19 per share, raising $316.3 million in gross proceeds to fund its blood cancer therapeutics development.
The biotechnology company will use the funds for preclinical studies, clinical trials, and manufacturing of its antibody programs targeting hematological cancers (搜索).
Galecto (搜索)'s pipeline includes a differentiated mutant calreticulin (搜索) portfolio for myeloproliferative neoplasms and GB3226 (搜索), a dual inhibitor for acute myeloid leukemia (搜索) treatment.
Galecto (搜索), Inc. (NASDAQ: GLTO) successfully closed its underwritten public offering on February 12, 2026, raising $316.3 million in gross proceeds to advance its pipeline of antibody therapeutics for blood cancers (搜索). The clinical-stage biotechnology company sold 16,644,737 shares of common stock at $19.00 per share, including the full exercise of underwriters' option to purchase an additional 2,171,052 shares.
Funding Strategy and Use of Proceeds
The substantial capital raise will support Galecto (搜索)'s comprehensive development strategy across multiple therapeutic programs. The company plans to allocate the proceeds toward preclinical studies, clinical trials, and manufacturing activities for its antibody programs. Additional funding will support expanded research and development activities, working capital requirements, and general corporate purposes.
Jefferies (搜索), Leerink Partners (搜索), Evercore ISI (搜索), and Guggenheim Securities (搜索) served as joint book-running managers for the offering, which was conducted through an automatically effective shelf registration statement filed with the Securities and Exchange Commission on February 10, 2026.
Therapeutic Pipeline Focus
Galecto (搜索)'s development portfolio centers on transforming treatment paradigms for hematological malignancies through innovative antibody therapeutics. The company's pipeline features a highly differentiated mutant calreticulin (搜索) (mut-CALR)-driven myeloproliferative neoplasm (搜索) portfolio specifically targeting essential thrombocythemia (搜索) and myelofibrosis (搜索).
Novel Dual Inhibitor Approach
A key component of Galecto (搜索)'s pipeline is GB3226 (搜索), described as a first-in-class preclinical dual inhibitor targeting both ENL-YEATS (搜索) and FLT3 (搜索) pathways. This therapeutic candidate is designed to address multiple genetic subsets of acute myeloid leukemia (搜索), representing a potentially significant advancement in treating this challenging blood cancer.
Market Response and Investor Confidence
The successful completion of the offering, including the full exercise of the underwriters' option for additional shares, demonstrates strong institutional investor confidence in Galecto (搜索)'s therapeutic approach and development strategy. The $19.00 per share pricing and substantial gross proceeds of $316.3 million position the company to advance its clinical programs through critical development milestones.
The offering structure also included an option for certain investors to receive Series C non-voting convertible preferred stock in lieu of common stock, with each preferred share convertible into 1,000 shares of common stock, subject to beneficial ownership conversion limits.